Market open
Agenus/$AGEN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Agenus
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Ticker
$AGEN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
389
Website
Agenus Metrics
BasicAdvanced
$88M
-
-$10.97
1.39
-
Price and volume
Market cap
$88M
Beta
1.39
52-week high
$19.69
52-week low
$2.50
Average daily volume
445K
Financial strength
Current ratio
0.185
Quick ratio
0.166
Long term debt to equity
-20.471
Total debt to equity
-29.016
Interest coverage (TTM)
-0.73%
Management effectiveness
Return on assets (TTM)
-21.95%
Return on equity (TTM)
120.92%
Valuation
Price to revenue (TTM)
0.467
Price to book
-0.28
Price to tangible book (TTM)
-0.25
Price to free cash flow (TTM)
-0.439
Growth
Revenue change (TTM)
59.00%
Earnings per share change (TTM)
-30.79%
3-year revenue growth (CAGR)
-19.42%
3-year earnings per share growth (CAGR)
215.29%
What the Analysts think about Agenus
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Agenus stock.
Agenus Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Agenus Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Agenus News
AllArticlesVideos
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
Business Wire·2 days ago
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
Business Wire·1 month ago
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Agenus stock?
Agenus (AGEN) has a market cap of $88M as of January 24, 2025.
What is the P/E ratio for Agenus stock?
The price to earnings (P/E) ratio for Agenus (AGEN) stock is 0 as of January 24, 2025.
Does Agenus stock pay dividends?
No, Agenus (AGEN) stock does not pay dividends to its shareholders as of January 24, 2025.
When is the next Agenus dividend payment date?
Agenus (AGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Agenus?
Agenus (AGEN) has a beta rating of 1.39. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.